Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4RVGO)

Drug Name
H-89 Drug Info
Synonyms H 89
Cross-matching ID
PubChem CID
449241
ChEBI ID
CHEMBL104264
CAS Number
CAS 127243-85-0
TTD Drug ID
D09FFE

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.66 0.00e+0 19/20 (95%) MSMO1;DHCR24;SQLE;...
Steroid hormone biosynthesis 2.50 0.00e+0 43/61 (70.49%) AKR1C3;HSD17B7;UGT2B28;...
Retinol metabolism 2.48 0.00e+0 41/68 (60.29%) UGT2B28;UGT2B4;CYP3A5;...
Metabolism of xenobiotics by cytochrome P450 2.44 0.00e+0 49/77 (63.64%) UGT2B28;UGT2B4;AKR1C1;...
PPAR signaling pathway 2.35 0.00e+0 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Terpenoid backbone biosynthesis 2.25 0.00e+0 18/22 (81.82%) HMGCS1;ACAT2;IDI1;...
Peroxisome 2.23 0.00e+0 72/82 (87.8%) IDH1;SLC27A2;ACSL3;...
Biosynthesis of unsaturated fatty acids 2.18 0.00e+0 21/27 (77.78%) SCD;FADS2;FADS1;...
Porphyrin and chlorophyll metabolism 2.12 0.00e+0 23/43 (53.49%) UGT2B28;UGT2B4;BLVRB;...
Cholesterol metabolism 2.11 0.00e+0 44/50 (88%) LDLR;CD36;APOA2;...
Pentose and glucuronate interconversions 2.03 6.19e-4 17/34 (50%) UGT2B28;UGT2B4;GUSB;...
Butanoate metabolism 2.00 5.67e-4 23/28 (82.14%) HMGCS1;ACAT2;HMGCS2;...
Ovarian steroidogenesis 2.00 5.24e-4 41/51 (80.39%) AKR1C3;HSD17B7;LDLR;...
Pentose phosphate pathway 1.95 9.72e-4 25/30 (83.33%) ALDOC;G6PD;RPIA;...
Synthesis and degradation of ketone bodies 1.89 1.82e-3 9/10 (90%) HMGCS1;ACAT2;HMGCS2;...
Complement and coagulation cascades 1.83 3.83e-3 76/85 (89.41%) FGB;FGG;F5;...
Nicotinate and nicotinamide metabolism 1.81 4.40e-3 25/35 (71.43%) QPRT;NNMT;SIRT3;...
Drug metabolism 1.81 4.16e-3 78/151 (51.66%) UGT2B28;UGT2B4;GSTA4;...
Bile secretion 1.81 4.30e-3 68/90 (75.56%) HMGCR;UGT2B28;LDLR;...
Ascorbate and aldarate metabolism 1.75 9.87e-3 15/30 (50%) UGT2B28;UGT2B4;GUSB;...
Valine, leucine and isoleucine degradation 1.73 1.26e-2 42/48 (87.5%) HMGCS1;ACAT2;HMGCS2;...
Mineral absorption 1.66 2.85e-2 48/60 (80%) FTH1;SLC26A6;CYBRD1;...
Glycosaminoglycan degradation 1.66 2.81e-2 19/19 (100%) GUSB;HGSNAT;NAGLU;...
Fatty acid degradation 1.64 2.95e-2 40/43 (93.02%) ACAT2;ACSL3;CPT1A;...
Lysosome 1.64 2.83e-2 115/128 (89.84%) MCOLN1;NEU1;CTSA;...
Arachidonic acid metabolism 1.62 3.82e-2 48/61 (78.69%) AKR1C3;ALOX15B;PTGIS;...
Pyruvate metabolism 1.59 4.66e-2 41/47 (87.23%) ACAT2;ACACA;ME1;...
Graft-versus-host disease -1.79 4.70e-2 32/42 (76.19%) FASLG;HLA-C;HLA-F;...
Type I diabetes mellitus -1.86 4.84e-2 38/43 (88.37%) FASLG;HLA-C;HLA-F;...
Allograft rejection -1.97 2.77e-2 32/38 (84.21%) FASLG;HLA-C;HLA-F;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.66uM - 10uM 6H, 24H